ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near San Francisco, CA, USA:

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Palo Alto, California, United States and 47 other locations

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...

Active, not recruiting
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Palo Alto, California, United States and 7 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

San Francisco, California, United States and 22 other locations

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...

Active, not recruiting
Acute Myeloid Leukemia
Biological: WU-NK-101

Phase 1

Wugen, Inc.

Palo Alto, California, United States and 8 other locations

agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodys...

Active, not recruiting
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: Azacitidine
Drug: Venetoclax

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Palo Alto, California, United States and 31 other locations

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...

Enrolling
Leukemia
Drug: Chemotherapy Agents
Drug: GDX012

Phase 1, Phase 2

Takeda
Takeda

Palo Alto, California, United States and 13 other locations

with relapsed or refractory B-cell acute lymphoblastic leukemia with high bone marrow lymphoblast percentage (\>50% lymphoblasts)....

Active, not recruiting
B-Cell Acute Lymphoblastic Leukemia, Adult
Drug: pembrolizumab
Drug: blinatumomab

Phase 1, Phase 2

University of California San Diego
University of California San Diego

San Francisco, California, United States and 3 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Oakland, California, United States and 43 other locations

of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia...

Enrolling
Lymphoblastic Leukemia
Drug: Mercaptopurine
Drug: Methotrexate

Phase 1, Phase 2

Tanja Andrea Gruber

Palo Alto, California, United States

chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Azacitidine

Phase 2

Mass General Brigham
Mass General Brigham

Palo Alto, California, United States and 8 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems